Compare OXLC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXLC | XNCR |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.0M | 881.9M |
| IPO Year | N/A | 2013 |
| Metric | OXLC | XNCR |
|---|---|---|
| Price | $9.75 | $12.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $6.00 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.5M | 818.2K |
| Earning Date | 11-01-2023 | 05-06-2026 |
| Dividend Yield | ★ 18.86% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $130,145,365.00 | $125,576,000.00 |
| Revenue This Year | $136.15 | N/A |
| Revenue Next Year | $5.51 | $4.80 |
| P/E Ratio | $8.31 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $3.18 | $6.92 |
| 52 Week High | $18.20 | $18.69 |
| Indicator | OXLC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 52.86 |
| Support Level | $8.11 | $12.29 |
| Resistance Level | $10.15 | $12.87 |
| Average True Range (ATR) | 0.29 | 0.78 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 77.27 | 65.18 |
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.